for people ages 18 years and up (full criteria)
at La Jolla, California and other locations
study started
completion around



The primary objective of this study is to evaluate the efficacy of atezolizumab plus tiragolumab and atezolizumab plus placebo as first-line (1L) treatment in recurrent/metastatic PD-L1-positive squamous cell carcinoma of the head and neck (SCCHN) on the basis of confirmed objective response rate. In addition, safety, pharmacokinetics, immunogenicity of atezolizumab and tiragolumab will be evaluated.

Official Title

A Phase II, Randomized, Double Blind Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck


Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell Carcinoma, Atezolizumab, Tiragolumab, Atezolizumab + Tiragolumab


You can join if…

Open to people ages 18 years and up

  • Histologically or cytologically confirmed recurrent/metastatic SCCHN involving the oropharynx, oral cavity, larynx, or hypopharynx, that is considered incurable by local therapies
  • Known results from human papillomavirus (HPV) status test for oropharyngeal carcinoma
  • No prior systemic therapy for metastatic and/or recurrent SCCHN
  • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  • Tumor PD-L1 expression as determined by PD-L1 immunohistochemistry assay
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Life expectancy >=12 weeks

You CAN'T join if...

  • Disease suitable for local therapy with curative intent
  • Progressive or recurrent disease within 6 months of the last dose of curative intent systemic treatment for locally advanced SCCHN
  • Rapidly progressing disease in the opinion of the treating investigator
  • Grade >=2 unresolved toxicity related to surgery or other prior therapies
  • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
  • History of leptomeningeal disease
  • Active or history of autoimmune disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • History of additional malignancy other than SCCHN within 5 years prior to randomization
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-TIGIT, anti-PD-L1, and anti-PD-1 therapeutic antibodies
  • Treatment with systemic immunostimulatory agents or systemic immunosuppressive medication
  • Pregnancy or breastfeeding


  • Moores Cancer Center at UC San Diego Health
    La Jolla California 92093 United States
  • UCLA
    Los Angeles California 90095 United States


in progress, not accepting new patients
Start Date
Completion Date
Hoffmann-La Roche
Phase 2 research study
Study Type
About 123 people participating
Last Updated